Protaffin Biotechnologie Ag

Antagonis Biotherapeutics Gmbh

Andreas Kungl

Christian Weber

Anna Maria Piccinini

The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.

Glycosaminoglycan-antagonising fusion proteins

Glycosaminoglycan-antagonising fusion proteins and methods of using same

Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.

Glycosaminoglycan-antagonising MCP-1 mutants

A method is provided for introducing a GAG binding site into a protein comprising the steps:

Growing community of inventors

Graz, Austria

Andreas Kungl